S 9788

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461664

CAS#: 140945-01-3

Description: S 9788 is a triazinoaminopiperidine derivative and a multidrug-resistance modulator.


Chemical Structure

img
S 9788
CAS# 140945-01-3

Theoretical Analysis

MedKoo Cat#: 461664
Name: S 9788
CAS#: 140945-01-3
Chemical Formula: C28H33F2N7
Exact Mass: 505.2766
Molecular Weight: 505.6178
Elemental Analysis: C, 66.51; H, 6.58; F, 7.51; N, 19.39

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: S 9788; S-9788; S9788;

IUPAC/Chemical Name: N2,N4-diallyl-6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)piperidin-1-yl)-1,3,5-triazine-2,4-diamine

InChi Key: GERNFWKTMKWULM-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H33F2N7/c1-3-15-31-26-34-27(32-16-4-2)36-28(35-26)37-17-13-24(14-18-37)33-19-25(20-5-9-22(29)10-6-20)21-7-11-23(30)12-8-21/h3-12,24-25,33H,1-2,13-19H2,(H2,31,32,34,35,36)

SMILES Code: C=CCNC1=NC(N2CCC(NCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)=NC(NCC=C)=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 505.6178 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP, Calvo F. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol. 1995;36(3):195-203. PubMed PMID: 7781138.

2: Efferth T, Dunn TA, Berlion M, Langenbahn H, Pommerenke EW, Volm M. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788. Anticancer Res. 1993 Jul-Aug;13(4):905-8. PubMed PMID: 8102519.

3: Cros S, Guilbaud N, Berlion M, Dunn T, Regnier G, Dhainaut A, Atassi G, Bizzari JP. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol. 1992;30(6):491-4. PubMed PMID: 1394807.

4: Oum'Hamed Z, Berlion M, Millot-Broglio C, Dufer J, Joly P, Bizzari JP, Desplaces A. [Quantitative cytological study of the activity of a new resistance modulator, S 9788, on human leukemic cells using multiparametric image analysis]. Bull Cancer. 1994 Mar;81(3):203-11. French. PubMed PMID: 7894128.

5: Tassin JP, Dubois J, Atassi G, Hanocq M. Simultaneous determination of cytotoxic (adriamycin, vincristine) and modulator of resistance (verapamil, S 9788) drugs in human cells by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1997 Apr 11;691(2):449-56. PubMed PMID: 9174283.

6: Le Bot MA, Kernaleguen D, Robert J, Berlion M, Riché C. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance. Cancer Chemother Pharmacol. 1994;35(1):53-8. PubMed PMID: 7987977.

7: Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Régnier G, Dhainaut A, Berlion M, Bizzari JP, Atassi G. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs. 1992 Aug;10(3):137-48. PubMed PMID: 1428723.

8: Bichat F, Solis-Recendez G, Poullain MG, Poupon MF, Khayat D, Bastian G. S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Biochem Pharmacol. 1998 Aug 15;56(4):497-502. PubMed PMID: 9763226.

9: Hu YP, Chapey C, Robert J. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett. 1996 Dec 3;109(1-2):203-9. PubMed PMID: 9020922.

10: Massart C, Gibassier J, Raoul M, Pourquier P, Leclech G, Robert J, Lucas C. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anticancer Drugs. 1995 Feb;6(1):135-46. PubMed PMID: 7756676.

11: Joly P, Lallemand A, Oum'Hamed Z, Trentesaux C, Idoine O, Desplaces A. Effects of verapamil and S9788 on MDR-1 mRNA expression studied by in situ hybridization. Anticancer Res. 1996 Nov-Dec;16(6B):3609-14. PubMed PMID: 9042229.

12: Dirson G, Fernandez C, Hindlet P, Roux F, German-Fattal M, Gimenez F, Farinotti R. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res. 2006 Jul;23(7):1525-32. Epub 2006 Jun 21. PubMed PMID: 16779703.

13: Demmer A, Dunn T, Hoof T, Kubesch P, Tümmler B. Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788. Eur J Pharmacol. 1996 Nov 21;315(3):339-43. PubMed PMID: 8982674.

14: Monnaert V, Betbeder D, Fenart L, Bricout H, Lenfant AM, Landry C, Cecchelli R, Monflier E, Tilloy S. Effects of gamma- and hydroxypropyl-gamma-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier. J Pharmacol Exp Ther. 2004 Dec;311(3):1115-20. Epub 2004 Jul 27. PubMed PMID: 15280439.

15: Rossi JF. Chemoresistance and multiple myeloma: from biological to clinical aspects. Stem Cells. 1995 Aug;13 Suppl 2:64-71. Review. PubMed PMID: 8520514.

16: Fenart L, Buée-Scherrer V, Descamps L, Duhem C, Poullain MG, Cecchelli R, Dehouck MP. Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm Res. 1998 Jul;15(7):993-1000. PubMed PMID: 9688050.

17: Cayre A, Moins N, Finat-Duclos F, Verrelle P, Maublant J. Comparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitro. J Nucl Med. 1997 Nov;38(11):1674-7. PubMed PMID: 9374331.

18: Massart C, Gibassier J, Raoul M, Denais A, Maugendre S, Darcel F, Lucas C. Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft. Anticancer Drugs. 1996 May;7(3):321-30. PubMed PMID: 8792007.

19: Léonce S, Pierré A, Anstett M, Pérez V, Genton A, Bizzari JP, Atassi G. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol. 1992 Nov 3;44(9):1707-15. PubMed PMID: 1360210.

20: Belhoussine R, Morjani H, Millot JM, Sharonov S, Manfait M. Confocal scanning microspectrofluorometry reveals specific anthracyline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. J Histochem Cytochem. 1998 Dec;46(12):1369-76. PubMed PMID: 9815278.